Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 15/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2010374 | 0.88 | HTR6 (0.44) | HTR6PPARGHDAC1 | |
| SCHEMBL2005850 | 0.88 | HTR6 (0.43) | HTR6HDAC1 | |
| SCHEMBL2005448 | 0.86 | HTR6 (0.53) | HTR6PPARGPPARDPPARAHDAC1 | |
| SCHEMBL2007388 | 0.81 | HTR6 (0.44) | HTR6NPSR1ALDH1A1PPARGPPARD | |
| SCHEMBL8144607 | 0.76 | NPSR1 (0.57) | NPSR1ALDH1A1TSHR | |
| SCHEMBL2008376 | 0.75 | HTR6 (0.54) | HTR6PPARGPPARDPPARAHDAC1 | |
| SCHEMBL2013231 | 0.73 | CPT1A (0.47) | HTR6PPARGPPARDPPARACYP3A4 | |
| SCHEMBL2001031 | 0.73 | PDE4A (0.47) | HTR6NPSR1ALDH1A1TSHRHDAC1 | |
| SCHEMBL2002520 | 0.73 | HTR6 (0.44) | HTR6 | |
| SCHEMBL2006265 | 0.73 | KCNH2 (0.48) | HTR6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200980-B9 | AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS FIELD OF INVENTION | SUVEN LIFE SCIENCES LTD (IN) | 2011-12-28 | — | — | EP | claimed |
| EP-2200980-B1 | AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS FIELD OF INVENTION | SUVEN LIFE SCIENCES LTD (IN) | 2011-08-03 | — | — | EP | claimed |
| US-7964627-B2 | Amino arylsulfonamide compounds and their use as 5-HT6 ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2011-06-21 | — | — | US | claimed |
| US-20100216861-A1 | AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-08-26 | — | — | US | claimed |
| EP-2200980-B9 | AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS FIELD OF INVENTION | SUVEN LIFE SCIENCES LTD (IN) | 2011-12-28 | — | — | EP | disclosed |
| EP-2200980-B1 | AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS FIELD OF INVENTION | SUVEN LIFE SCIENCES LTD (IN) | 2011-08-03 | — | — | EP | disclosed |
| US-7964627-B2 | Amino arylsulfonamide compounds and their use as 5-HT6 ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2011-06-21 | — | — | US | disclosed |
| US-20100216861-A1 | AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216861-A1 | AMINO ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | HTR6, HTR5A, HTR1A | HTR6 1/4885NPSR1 22/4885ALDH1A1 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.